Novartis Ag (NVSEF) Depreciation & Amortization (CF) (2009 - 2018)

Novartis Ag's (NVSEF) quarterly Depreciation & Amortization (CF) came in at $930.0 million in Q1 2018, up 139849524.06% quarter-over-quarter from $665.0 in Q2 2010.

Novartis Ag (NVSEF) Depreciation & Amortization (CF) (2009 - 2018) Analysis & Trends

Novartis Ag has disclosed Depreciation & Amortization (CF) across 3 years of filings, most recently posting $930.0 million for Q1 2018.

  • Depreciation & Amortization (CF) for Q1 2018 came in at $930.0 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2018 was $930.0 million (changed N/A YoY), and the FY2009 annual result was $2341.0, changed N/A from the prior year.
  • Depreciation & Amortization (CF) came in at $930.0 million for Q1 2018 at Novartis Ag, up from $665.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $930.0 million in Q1 2018 to a low of $930.0 million in Q1 2018.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Depreciation & Amortization (Qtr)
1 Gsk 93,699,046.73 Bn 93,699,041.77 Bn 7.76 Bn -
2 Eli Lilly 1,012.06 Bn 1,006.77 Bn 16.22 Bn 509.00 Mn
3 Johnson & Johnson 560.67 Bn 538.62 Bn 15.96 Bn 2.00 Bn
4 AbbVie 402.20 Bn 392.85 Bn 10.78 Bn 188.00 Mn
5 Merck 298.59 Bn 292.94 Bn 12.09 Bn 581.00 Mn
6 Amgen 188.77 Bn 176.74 Bn 5.87 Bn 1.12 Bn
7 Gilead Sciences 160.22 Bn 152.49 Bn 5.52 Bn 93.00 Mn
8 Pfizer 148.19 Bn 135.42 Bn -1.21 Bn 1.61 Bn
9 Bristol Myers Squibb 116.72 Bn 106.26 Bn 8.07 Bn 594.00 Mn
10 Novartis Ag - - - -

Historic Data

Download Data
DateValue
Mar 31, 2018 930.00 Mn
Mar 31, 2018 930.00 Mn
Jun 30, 2010 665.00
Jun 30, 2010 665.00
Mar 31, 2010 761.00
Mar 31, 2010 761.00
Dec 31, 2009 629.00
Dec 31, 2009 629.00
Sep 30, 2009 614.00
Sep 30, 2009 614.00
Jun 30, 2009 550.00
Jun 30, 2009 550.00
Mar 31, 2009 548.00
Mar 31, 2009 548.00